BL Pharmtech Corp.
Financials
Valuation Metrics
BL Pharmtech Corp.'s Market Cap is ₩638B. At end of 2025 it was ₩153B. Ranked #1611 of 2,421 in KR market (top 67%), #954 of 1,640 on KOSDAQ (top 58%), #33 of 57 in Household & Personal Products (top 58%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 63.78B KRW | KR#1,611/2,421 Sec#33/57 |
| Revenue | 3.95B KRW | KR#2,354/2,421 Sec#56/57 |
| Net Income | -15.15B KRW | KR—/2,421 Sec—/57 |
| Total Assets | 17.07B KRW | KR#2,387/2,421 Sec#56/57 |
| Net Assets | 8.35B KRW | KR#2,381/2,421 Sec#57/57 |
| Employees | 16 | KR#2,269/2,421 Sec#56/57 |
| Value | ||
| P/B | 7.64x | KR#2,324/2,421 Sec#55/57 |
| P/S | 16.16x | KR#2,323/2,421 Sec#56/57 |
| Profitability | ||
| ROE | -181.49% | KR#2,376/2,421 Sec#57/57 |
| ROA | -88.77% | KR#2,393/2,421 Sec#57/57 |
| Op. Margin | -52.70% | KR#2,239/2,421 Sec#53/57 |
| Revenue Growth | -54.27% | KR#2,299/2,421 Sec#57/57 |
| Financial Health | ||
| Debt Ratio | 104.46% | KR#1,601/2,421 Sec#43/57 |
| Total Debt | 3.08B KRW | KR#1,859/2,421 Sec#42/57 |
| Cash | 5.79B KRW | KR#1,956/2,421 Sec#43/57 |
| Current Ratio | 0.95x | KR#1,782/2,421 Sec#38/57 |
| Performance | ||
| 1Y Return | 215.61% | KR#44/2,421 Sec#1/57 |
| 1M Return | 22.52% | KR#207/2,421 Sec#3/57 |
| From 52W High | -71.96% | KR#2,235/2,421 Sec#53/57 |
| 1Y MDD | -76.39% | KR#2,223/2,421 Sec#52/57 |
| Trading | ||
| Volume | 377,848 shares | KR#302/2,421 Sec#4/57 |
| Trading Value | 868.1M KRW | KR#758/2,421 Sec#21/57 |
| Foreign Own. | 1.36% | KR#1,887/2,421 Sec#36/57 |
| Per Share | ||
| EPS | -543 KRW | KR—/2,421 Sec—/57 |
| BPS | 299 KRW | KR#2,409/2,421 Sec#57/57 |
Company Info
BL Pharmtech, established in 1995 and listed on KOSDAQ in 2002, is a specialized healthcare distribution company. It distributes health functional foods and general foods, and manufactures and sells in-vitro diagnostic medical devices, owning brands NFP, Boidang, and ramen brand Mister Min. Leveraging 30 years of distribution experience, the company has built extensive online and offline distribution networks. BL Pharmtech is diversifying its healthcare operations by entering the European ready-to-eat food market and expanding its diagnostic kit business. It is headquartered in Gyeonggi-do, Yongin-si.